---
document_datetime: 2025-12-29 11:53:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/chenodeoxycholic-acid-leadiant.html
document_name: chenodeoxycholic-acid-leadiant.html
version: success
processing_time: 0.1283012
conversion_datetime: 2025-12-30 01:15:42.732056
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau)

[RSS](/en/individual-human-medicine.xml/67004)

##### Authorised

This medicine is authorised for use in the European Union

chenodeoxycholic acid Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau)](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78651)
- [More information on Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Chenodeoxycholic acid Leadiant. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Chenodeoxycholic acid Leadiant.

For practical information about using Chenodeoxycholic acid Leadiant, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Chenodeoxycholic acid Leadiant and what is it used for?

Chenodeoxycholic acid Leadiant is a medicine that contains the active substance chenodeoxycholic acid. This is a 'primary bile acid', which is a main component of bile (a fluid produced by the liver that helps to digest fats).

Chenodeoxycholic acid Leadiant is used to treat adults and children from one month of age with cerebrotendinous xanthomatosis. These patients cannot produce enough of the primary bile acid chenodeoxycholic acid due to genetic abnormalities that result in a lack of the liver enzyme sterol 27 hydroxylase. When primary bile acids are lacking, the body produces abnormal bile acids and other substances instead which accumulate throughout the body, causing damage.

Because the number of patients with this condition is low, the disease is considered 'rare', and Chenodeoxycholic acid Leadiant was designated an 'orphan medicine' (a medicine used in rare diseases) on 16 December 2014.

Chenodeoxycholic acid Leadiant is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance. The reference medicine for Chenodeoxycholic acid Leadiant is Xenbilox. However, Xenbilox differs from Chenodeoxycholic acid Leadiant in that it is authorised for a different use (to dissolve cholesterol gallstones).

## How is Chenodeoxycholic acid Leadiant used?

Chenodeoxycholic acid Leadiant can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in treating cerebrotendinous xanthomatosis or other diseases of primary bile acid production.

Chenodeoxycholic acid Leadiant is available as capsules (250 mg) which are taken 3 times a day at approximately the same time every day. The daily dose is chosen and adjusted during treatment for each patient depending on the patient's age, liver function and levels of bile acids in their blood and urine. For small children and children who cannot swallow capsules, the contents of the capsules can be mixed with sodium bicarbonate solution 8.4% to make a liquid.

For further information, see the package leaflet.

## How does Chenodeoxycholic acid Leadiant work?

Chenodeoxycholic acid is one of the main primary bile acids produced by the liver. The chenodeoxycholic acid contained in this medicine replaces the patient's missing chenodeoxycholic acid. This helps to reduce the production of abnormal substances and contributes to the normal activity of bile in the digestive system, thereby relieving the symptoms of the disease.

## What benefits of Chenodeoxycholic acid Leadiant have been shown in studies?

Chenodeoxycholic acid Leadiant has been investigated in a study which looked at the records of 35 patients with cerebrotendinous xanthomatosis who received chenodeoxycholic acid for around 9 years. Among 23 patients for whom data on blood levels of bile acids were available, all had reductions in their levels (average reduction of 56-69 µmol/l). Among 14 patients for whom data on urine levels of bile acids were available, 79% (11 out of 14) had reduced levels at their most recent test. Most patients also had improvements in symptoms of the disease: all reported an improvement in diarrhoea, 89% of patients showed an improvement in their mental ability, 60% of patients showed improvement in mobility, and 85% and 77% of patients showed psychiatric improvement based on two different scores.

## What are the risks associated with Chenodeoxycholic acid Leadiant?

The side effects seen with Chenodeoxycholic acid Leadiant are constipation and abnormal liver test values; however their frequency could not be reliably estimated from the available limited data. They were mild or moderate in severity and did not last.

For the list of restrictions, see the package leaflet.

## Why is Chenodeoxycholic acid Leadiant approved?

Chenodeoxycholic acid has been used to treat cerebrotendinous xanthomatosis for about 40 years, although it was not licensed for this use. However, due to the rarity of the disease, there are still limited data available on the use of the medicine. Nevertheless, studies have shown that the medicine benefits patients and has no significant side effects. The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Chenodeoxycholic acid Leadiant's benefits are greater than its risks and recommended that it be approved for use in the EU.

Chenodeoxycholic acid Leadiant has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Chenodeoxycholic acid Leadiant due to the rarity of the disease. Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.

## What information is still awaited for Chenodeoxycholic acid Leadiant?

Since Chenodeoxycholic acid Leadiant has been approved under exceptional circumstances, the company that markets this medicine will set up a registry to monitor the benefits and safety of the medicine.

## What measures are being taken to ensure the safe and effective use of Chenodeoxycholic acid Leadiant?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Chenodeoxycholic acid Leadiant have been included in the summary of product characteristics and the package leaflet.

## Other information about Chenodeoxycholic acid Leadiant

The European Commission granted a marketing authorisation valid throughout the European Union for Chenodeoxycholic acid sigma-tau on 10 April 2017. The name of the product was changed to Chenodeoxycholic acid Leadiant on 12 May 2017.

For more information about treatment with Chenodeoxycholic acid Leadiant, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Chenodeoxycholic acid Leadiant : EPAR - Summary for the public

Reference Number: EMA/628674/2016

English (EN) (81.68 KB - PDF)

**First published:** 05/05/2017

**Last updated:** 29/06/2017

[View](/en/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-721)

български (BG) (125.72 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/bg/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_bg.pdf)

español (ES) (104.33 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/es/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_es.pdf)

čeština (CS) (108.57 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/cs/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_cs.pdf)

dansk (DA) (101.74 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/da/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_da.pdf)

Deutsch (DE) (107.07 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/de/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_de.pdf)

eesti keel (ET) (100.44 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/et/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_et.pdf)

ελληνικά (EL) (157.63 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/el/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_el.pdf)

français (FR) (106.84 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/fr/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_fr.pdf)

hrvatski (HR) (105.27 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/hr/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_hr.pdf)

italiano (IT) (105.08 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/it/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_it.pdf)

latviešu valoda (LV) (135.8 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/lv/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (106.75 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/lt/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_lt.pdf)

magyar (HU) (107.25 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/hu/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_hu.pdf)

Malti (MT) (192.6 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/mt/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_mt.pdf)

Nederlands (NL) (105.11 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/nl/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_nl.pdf)

polski (PL) (108.66 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/pl/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_pl.pdf)

português (PT) (103.62 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/pt/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_pt.pdf)

română (RO) (105.02 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/ro/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_ro.pdf)

slovenčina (SK) (109.48 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/sk/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_sk.pdf)

slovenščina (SL) (104.15 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/sl/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_sl.pdf)

Suomi (FI) (101.41 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/fi/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_fi.pdf)

svenska (SV) (102.74 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/sv/documents/overview/chenodeoxycholic-acid-leadiant-epar-summary-public_sv.pdf)

## Product information

Chenodeoxycholic acid Leadiant : EPAR - Product Information

English (EN) (403.22 KB - PDF)

**First published:** 05/05/2017

**Last updated:** 13/08/2025

[View](/en/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-985)

български (BG) (499.2 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/bg/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_bg.pdf)

español (ES) (416.04 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/es/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_es.pdf)

čeština (CS) (412.79 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/cs/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_cs.pdf)

dansk (DA) (397.57 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/da/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_da.pdf)

Deutsch (DE) (432.68 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/de/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_de.pdf)

eesti keel (ET) (370.06 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/et/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_et.pdf)

ελληνικά (EL) (503.88 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/el/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_el.pdf)

français (FR) (438.19 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/fr/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_fr.pdf)

hrvatski (HR) (547.81 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/hr/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_hr.pdf)

íslenska (IS) (404.28 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/is/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_is.pdf)

italiano (IT) (377.57 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/it/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_it.pdf)

latviešu valoda (LV) (461.49 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/lv/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_lv.pdf)

lietuvių kalba (LT) (451.81 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/lt/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_lt.pdf)

magyar (HU) (484.54 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/hu/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_hu.pdf)

Malti (MT) (499.44 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/mt/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_mt.pdf)

Nederlands (NL) (407.39 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/nl/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_nl.pdf)

norsk (NO) (431.72 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/no/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_no.pdf)

polski (PL) (492.64 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/pl/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_pl.pdf)

português (PT) (381.58 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/pt/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_pt.pdf)

română (RO) (523.41 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/ro/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_ro.pdf)

slovenčina (SK) (409.73 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/sk/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_sk.pdf)

slovenščina (SL) (472.86 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/sl/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_sl.pdf)

Suomi (FI) (344.15 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/fi/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_fi.pdf)

svenska (SV) (415.85 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

13/08/2025

[View](/sv/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMEA/H/C/PSUSA/00010590/202410 23/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Chenodeoxycholic acid Leadiant : EPAR - All Authorised presentations

English (EN) (19.88 KB - PDF)

**First published:** 05/05/2017

**Last updated:** 29/06/2017

[View](/en/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-588)

български (BG) (44.94 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/bg/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.78 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/es/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.8 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/cs/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.92 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/da/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.93 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/de/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (18.97 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/et/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.01 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/el/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_el.pdf)

français (FR) (18.92 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/fr/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.2 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/hr/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.88 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/is/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.93 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/it/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.54 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/lv/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.51 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/lt/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.74 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/hu/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.66 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/mt/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.96 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/nl/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.89 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/no/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.91 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/pl/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.03 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/pt/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.24 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/ro/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (37.79 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/sk/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (20.6 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/sl/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.62 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/fi/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.74 KB - PDF)

**First published:**

05/05/2017

**Last updated:**

29/06/2017

[View](/sv/documents/all-authorised-presentations/chenodeoxycholic-acid-leadiant-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau) Active substance chenodeoxycholic acid International non-proprietary name (INN) or common name chenodeoxycholic acid Therapeutic area (MeSH)

- Xanthomatosis, Cerebrotendinous
- Metabolism, Inborn Errors

Anatomical therapeutic chemical (ATC) code A05AA01

### Pharmacotherapeutic group

Bile and liver therapy

### Therapeutic indication

Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults.

## Authorisation details

EMA product number EMEA/H/C/004061

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Leadiant GmbH

Liebherrstrasse 22

Opinion adopted 21/07/2016 Marketing authorisation issued 10/04/2017 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Chenodeoxycholic acid Leadiant : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (154.31 KB - PDF)

**First published:** 29/06/2017

**Last updated:** 13/08/2025

[View](/en/documents/procedural-steps-after/chenodeoxycholic-acid-leadiant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Chenodeoxycholic acid Leadiant-H-C-PSUSA-00010590/202410 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/162480/2025

English (EN) (117.89 KB - PDF)

**First published:** 13/08/2025

[View](/en/documents/scientific-conclusion/chenodeoxycholic-acid-leadiant-h-c-psusa-00010590-202410-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Chenodeoxycholic acid sigma-tau : EPAR - Public assessment report

Adopted

Reference Number: EMA/650359/2016

English (EN) (1.19 MB - PDF)

**First published:** 05/05/2017

**Last updated:** 05/05/2017

[View](/en/documents/assessment-report/chenodeoxycholic-acid-sigma-tau-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Chenodeoxycholic acid sigma-tau

Adopted

Reference Number: EMA/CHMP/542534/2016

English (EN) (62.64 KB - PDF)

**First published:** 16/09/2016

**Last updated:** 16/09/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-chenodeoxycholic-acid-sigma-tau_en.pdf)

#### News on Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2016-corrected) 21/09/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0040610000) (initial marketing authorisation)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Chenodeoxycholic acid Leadiant : EPAR - Product Information (tracked changes)

English (EN) (82.8 KB - DOCX)

**First published:** 13/08/2025

[View](/en/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-679)

български (BG) (200.5 KB - DOC)

**First published:**

13/08/2025

[View](/bg/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_bg.doc)

español (ES) (203 KB - DOC)

**First published:**

13/08/2025

[View](/es/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_es.doc)

čeština (CS) (73.87 KB - DOCX)

**First published:**

13/08/2025

[View](/cs/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_cs.docx)

dansk (DA) (186 KB - DOC)

**First published:**

13/08/2025

[View](/da/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_da.doc)

Deutsch (DE) (70.93 KB - DOCX)

**First published:**

13/08/2025

[View](/de/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_de.docx)

eesti keel (ET) (197.5 KB - DOC)

**First published:**

13/08/2025

[View](/et/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_et.doc)

ελληνικά (EL) (296.5 KB - DOC)

**First published:**

13/08/2025

[View](/el/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_el.doc)

français (FR) (211 KB - DOC)

**First published:**

13/08/2025

[View](/fr/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_fr.doc)

hrvatski (HR) (226.5 KB - DOC)

**First published:**

13/08/2025

[View](/hr/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_hr.doc)

íslenska (IS) (203 KB - DOC)

**First published:**

13/08/2025

[View](/is/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_is.doc)

italiano (IT) (262.5 KB - DOC)

**First published:**

13/08/2025

[View](/it/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_it.doc)

latviešu valoda (LV) (213.5 KB - DOC)

**First published:**

13/08/2025

[View](/lv/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_lv.doc)

lietuvių kalba (LT) (58.25 KB - DOCX)

**First published:**

13/08/2025

[View](/lt/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_lt.docx)

magyar (HU) (218.5 KB - DOC)

**First published:**

13/08/2025

[View](/hu/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_hu.doc)

Malti (MT) (191 KB - DOC)

**First published:**

13/08/2025

[View](/mt/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_mt.doc)

Nederlands (NL) (205.5 KB - DOC)

**First published:**

13/08/2025

[View](/nl/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_nl.doc)

norsk (NO) (67.51 KB - DOCX)

**First published:**

13/08/2025

[View](/no/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_no.docx)

polski (PL) (69.66 KB - DOCX)

**First published:**

13/08/2025

[View](/pl/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_pl.docx)

português (PT) (208.5 KB - DOC)

**First published:**

13/08/2025

[View](/pt/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_pt.doc)

română (RO) (224.5 KB - DOC)

**First published:**

13/08/2025

[View](/ro/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_ro.doc)

slovenčina (SK) (236.5 KB - DOC)

**First published:**

13/08/2025

[View](/sk/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_sk.doc)

slovenščina (SL) (207.5 KB - DOC)

**First published:**

13/08/2025

[View](/sl/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_sl.doc)

Suomi (FI) (232.5 KB - DOC)

**First published:**

13/08/2025

[View](/fi/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_fi.doc)

svenska (SV) (70.21 KB - DOCX)

**First published:**

13/08/2025

[View](/sv/documents/product-information-tracked-changes/chenodeoxycholic-acid-leadiant-epar-product-information_sv.docx)

#### More information on Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau)

- [EU/3/14/1406 - orphan designation for treatment of inborn errors in primary bile acid synthesis](/en/medicines/human/orphan-designations/eu-3-14-1406)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/08/2025

## Share this page

[Back to top](#main-content)